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Abstract
Alzheimer’s and other neurodegenerative diseases are generally incurable and often diffi-
cult to diagnose accurately. Yet early and accurate diagnosis of a neurodegenerative disease
can potentially contribute to more effective treatment. Hence research efforts are moving
towards early identification of high risk subjects and prevention of disease progression with
biomarkers. Unfortunately dementia and biomarker studies are hampered by variables
such as drop outs, challenges in comparing data sets, discordant biomarker sets, availability
of histopathological confirmation at death, validity of cognitive testing, and nonlinear
fluctuations in cognitive domains as disease progresses in vivo in subjects. This chapter is
an assessment of the challenges in the early diagnosis of dementia, as well as a presentation
of the issues faced in conducting dementia and biomarker studies.
Keywords: Alzheimer’s disease, dementia, mild cognitive impairment, ageing, early
diagnosis, biomarkers, research
1. Introduction
Although dementia is a priority for research globally, dementia studies are very complicated to
design [1, 2]. Patents have a time limit which might expire prior to completing a trial, thus compli-
cating contracts with a pharmaceutical company to use their drugs. Drug studies may involve
issues related to the use of biomarkers which have not been validated for such use, like disclosure
of biomarker results to participants. The treatment target for best outcome is still unestablished, and
there areno guarantees that any treatmentwillwork. In addition the odds of success are poor based
on a string of crushingdefeats so far [3, 4]. Pharmaceuticals pull out of trials because of the price and
risk of not succeeding. Due to the slowly progressive nature of dementia, there is a huge time-lag
between the commencement of trials and obtaining results. Dementia covers a multitude of
specialities, including neurologists, geriatricians, nuclear medicine physicians, radiologists,
psychogeriatricians, pathologists, and psychologists. Collaboration with colleagues from different
sub-specialities andwith regulatory agencies is needed to successfully conduct studies.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In any diagnostic entity, there is increased heterogeneity the earlier it is addressed, and so mild
cognitive impairment (MCI) is a challenging population to study due to the heterogenous
phenotypes, etiologies and prognosis, both cross-sectionally and longitudinally. Furthermore,
similar symptoms can often be attributed to multiple different causes, each to varying degrees.
Although there is a good amount of consistency between MCI studies themselves, increased
heterogeneity in the actual early disease states does result in differences in outcome between
MCI studies. The new research criteria for MCI due to Alzheimer’s disease (AD) is an attempt
to eventually move beyond highlighting MCI as a major risk factor for AD to operationalizing
the prognostication of cognitive impairment in clinical settings.
This chapter considers the methodological issues, challenges and assumptions that need to be
taken into consideration when evaluating dementia and biomarker studies.
2. Challenges in data acquisition and analysis
2.1. Challenges in recruiting participants for dementia studies
Longitudinal studies are better at establishing causal directions than are cross-sectional stud-
ies. However it is not easy to recruit MCI participants, especially for a longitudinal dementia
study [5]. Factors affecting eligibility for enrolment include lack of awareness of the trial, lack
of benefits to the participant, stringent enrolment criteria which may exclude many people,
older age of study volunteers, co-morbidity factors, disability, lack of mobility, requiring the
cooperation of a partner or carer, transportation, administration of medication, too many tests,
and intensive monitoring of the individual’s condition and progress. In general, dementia
trials usually take at least 5–6 years to discover whether a drug works or not, due to slow
enrolment [6, 7]. Ramifications of this include slow development of potential new treatment,
increased costs associated with clinical trials, and impact on the reliability of trial results due to
changes which include scanners, investigators, personnel, and economic cycles.
In order to improve internal validity, studies may seek to make recruitment criteria more
stringent so as to reduce the heterogeneity typically seen in a memory clinic. Yet in order for
studies to be more relevant to clinicians, they also need to be anchored clinically, which means
recruitment criteria cannot be too tough for participants to be enrolled. One way to increase the
number of volunteers is to simplify recruitment enrolment criteria and screening processes. By
being less stringent on suitable subjects for recruitment, more can be eligible for enrolment
which helps to encourage referrals from clinicians.
2.2. Leveraging data sets
The support for small studies with less statistical and mathematical rigour to detect or demon-
strate a response may be just as important as large randomised controlled trials to validate a
response. Justifying resources to be spent on designing and running a study first requires more
than just a good idea, but also supporting data from smaller studies, as well as available time-
frame and interest. While big studies are often desirable for improving validity, relatively
smaller longitudinal studies may be no less significant in exposing a scientific law, if data was
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collected and analysed the right way. We should remember that the modern science of genetics
was founded on cross breeding yellow and green peas and their offsprings, at a time when
many competing theories were making headway.
Research efforts are moving towards early identification of high risk subjects and prevention of
progression. In the preclinical space, there is not yet a lot of longitudinal biomarker data.
Longitudinal data provides important knowledge of biomarkers in predicting and monitoring
cognitive and functional decline. To make the most of the limited data, use of both familiar as
well as more sophisticated statistical techniques is required. There is a need for equations and
formulas that can embrace heterogeneity without being too complex.
The Cox regression survival analysis is one statistical approach that can distill the heterogene-
ity of MCI aetiologies to determine independent risk factors for MCI conversion to AD. Cox
regression is a survival analysis statistical technique that enables the simultaneous comparison
and adjustment of the effects of several risk factors (i.e. the predictor variables or covariates) of
an unwanted event occurring. It can also accommodate covariates that are dichotomous,
continuous, and even if they might change in value. The required inputs are: time to an
unwanted event of interest, the unwanted event of interest, and the predictor variables. The
result is expressed as hazard ratios, which is the proportion of an unwanted event of interest
between groups at an instantaneous moment in time. According to the Cox regression model,
the hazard for an individual is a fixed hazard for any other individual. By inputting all known
variables (risk factors) in a study cohort into the Cox model, we can adjust for all of them
simultaneously.
2.3. Source of subjects, where and when the study was conducted
The source of subjects is a significant point that affects rates of conversion to AD [8]. People
seeking specialist care for memory loss are more selected compared with people in the commu-
nity who happen to have some memory problems [9]. Different studies have different aims and
designs, and different methods to operationalize criteria [7]. Cognitive complains can be sponta-
neous, yet not routinely elicited in some cases; and clinical assessments can be standardised in
some cases but based on more subjective clinical judgement in others.
Recruitment sites are an important consideration in designing studies. Cohorts at different sites
are demographically different in some ways, so academic sites perform differently from commer-
cial sites. Some cohorts like the Australian Imaging Biomarkers and Lifestyle healthy control
cohort are Apolipoprotein E ε4 (E4) enriched [10]. The Alzheimer’s Disease Neuroimaging Initia-
tive (ADNI) cohort consists of 398 MCI subjects, who were mostly white and highly educated,
had intermediate cognitive measures and cerebral spinal fluid (CSF) biomarker levels between the
ADNI controls and AD groups [11], and there was also a high proportion of E4 carriers.
MCI cohorts recruited today may not be entirely relevant to tomorrow’s world. Secular changes
influence the predictive value of cognitive performance in dementia. For example, in the Flynn
Effect [12], massive gains in IQ of Americans were observed between 1932 and 1978. Humanity
seems to gain skills that make IQ tests outdated. Lifestyle technology development like software
apps may further leverage our function and so delay residential care.
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2.4. Challenges in comparing data sets
Retrofitting criteria and statistical models developed from experience with one cohort to
another that has different demographic characteristics will end up with varying outcomes,
not to mention the different combinations of measurements, cut-offs, number of subjects,
and length of follow-up between samples that will further compound the variability of
results [13–17].
Validity is gained when results are repeatable. Power is gained when shared data is combined.
Sometimes data sets are easily comparable. For example, the ability of 3.0-Tesla (T) and 1.5-T
scanners to track longitudinal atrophy in AD and MCI patients using tensor based morphom-
etry are both similar and powerful enough to detect atrophy longitudinally [18], so it may not
matter much that one cohort had their magnetic resonance imaging (MRI) on a 1.5-T scanner
and another cohort had their MRI on a 3.0-T scanner. However in dementia studies, combining
data sets is not a trivial issue. Comparing results from different studies that have used different
methodologies is rather difficult. Combining data from different scanners introduces noise.
Different positron emission tomography (PET) or MRI scanners have different scanner and
software combinations. Inter scanner variability is excluded if all cross-sectional and longitu-
dinal scans are performed on the same scanner—but this is not practical.
Lack of standardisation threatens to hamper the comparison and replication of results, increase
analytical variability, and complicate the evaluation of methods [7]. Different methods of
biomarker analyses give varying degrees of precision [19]. Drop outs or missing data are dealt
with differently. Time lag between receiving a clinical diagnosis of subjective cognitive impair-
ment (SCI) or MCI and enrolment differs between studies. If the time lag between diagnosis
and recruitment is long, this might make one SCI or MCI cohort have more stable subjects, and
so less likely to progress to a dementia subtype. Different population norms are used for
neuropsychological tests, and different batteries of neuropsychological tests are used.
Given that the stability of cognition can be affected by many factors in the short term, it is
important to consider what variables are corrected for when we read published studies. As
mentioned above, a down side to robustly designed studies which are generally informative as
they control for many factors, is that they may not simulate routine clinical practice well.
2.5. Drop outs and their risk factors
Drop outs in research studies due to relocation and loss of interest should be classified as
random dropouts. However drop outs from MCI studies are not entirely random [20]. Tradi-
tional survival analysis assumes censored observations are non-informative and ignorable [21].
Yet death alters the probability of observing dementia.
Risk factors for cognitive and functional impairments in MCI can also be risk factors for
dropping out early from MCI studies causing potential bias in the sample. For example, E4 is
a risk factor for progression from a clinical dementia rating (CDR) of 0.5 to a CDR of 1 and
above and a risk factor for cardiovascular mortality [22]. Heart failure is a risk factor for
progression from mild cognitive to severe cognitive impairment, and for functional decline
[23]. Stroke is a risk factor for non-amnestic cognitive and functional decline [24].
Alzheimer's Disease - The 21st Century Challenge112
A joint modelling approach can potentially reduce the bias which attenuates the effect of
neuropathology on cognitive decline. This bias occurs if non-random drop outs are excluded
from analyses, or if the last observation carried forward method is used.
3. Diagnostic challenges
3.1. Accuracy of diagnosis
The dementia field is filled with many contradictory ideas and controversies. Accuracy of
dementia diagnoses has been an unresolved challenge. For example, in the religious orders
study involving over 1000 nuns, the majority of cases particularly in those over 85 have AD
pathology as well as several other pathologies [25]. Of the phenotypes that look like clini-
cally probable AD, some had Lewy bodies or other predominant neurodegenerative disor-
ders at autopsy.
3.2. Volatility of clinical outcomes
Diagnosing during the pre-dementia stages is challenged by fluctuations in cognitive ability
over long periods of time [26]. In short term MCI studies, outcomes are rather volatile, such
that one can revert to normal, remain MCI with improvement or deterioration in cognitive
abilities, convert to dementia, improve after deteriorating further, or deteriorate again after
improving. For example, in the Rochester Minnesota longitudinal study, as high as 35% of
MCI reverted to normal when followed long enough [27]. However two-thirds of these
ultimately progressed again to MCI or dementia. In the Pittsburgh longitudinal health study
after over a decade of follow-up, a small percent return to normal after being diagnosed with
MCI [28].
One way to account for the observed volatility is the rigid way disease and states are categorised.
By taking a disease continuum and subjecting it to arbitrary boundaries, patients are likely to
bounce in and out of them. Another cause of volatility is the random fluctuation of cognitive test
scores up to half a standard deviation. Someone vulnerable near the cut-off could be having a
good day and so their scores may be considered to be within the normal range, or having a bad
day and so their scores may be considered to be within the MCI range. This variability of
performance from day to day is not a trivial matter because it predicts future decline over and
beyond cognitive performance [29]. Consecutive clinical information should be taken more
seriously as it may discount initial diagnoses.
The entire trajectory of cognitive decline in one at risk of AD is not necessarily due solely to
AD. To date only up to half of cognitive decline can be accounted for by neuropathology seen
on autopsies of brains, e.g. AD, micro and macro infarcts, Lewy bodies, TDP-43, pre-synaptic
proteins, and neuronal density and locus [30]. Pathology may trigger events or formation of
other pathologies, thus causing people’s brains to differ in how they respond to the predomi-
nant neurodegenerative pathology. For example, mixed AD with Lewy Bodies will have more
variability in their cognition due to attention impairment [31].
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3.3. The paradox of Alzheimer’s disease biomarker validation studies
High quality studies validating the diagnostic utility of biomarkers involve blinding of clinicians
to the biomarker results when making a clinical diagnosis, and blinding assessors of the bio-
markers to the clinical diagnoses. However the diagnosis of clinically probable AD using standard
criteria has an error rate of at least 20%, and definite diagnosis requires confirmatory pathology
[32]. Hence no biomarker study can outweigh the quality of the clinical diagnosis even if double
blinding is the gold standard. Unblinding a clinician to an amyloid PET scan result introduces
circularity in the validation of the amyloid PET scan. However doing so has value as it may
actually improve the certainty of an AD diagnosis or correct a wrong diagnosis of AD.
3.4. Qualitative versus quantitative approach to diagnosis
The ability to accurately diagnose the clinical group to which a subject belongs is a crucial first
step for appropriate management, and for clinical trial design. Categorising participants into
MCI subtypes is heavily reliant on cross-sectional performance on neuropsychological tests as
compared with a matched normal cohort. However, clinical assessment rather than quantita-
tive variables takes precedence in assigning individuals into a dementia subtype. The problem
with basing the MCI criteria on objective scores is that objective scores which are arbitrarily
defined are required to support the subjective complains of symptoms which fluctuate. This
system of categorising MCI helps to define MCI subgroups to facilitate research studies, but
adds confusion when applied to assessing individuals. It has been observed in the ADNI
cohorts that study variables have significant overlap between clinical groups, and that groups
differ more qualitatively than quantitatively [33].
3.5. Conundrums in dementia studies
Even with histopathological confirmation of a definite AD diagnosis at death, it can be argued
that there is always a degree of circularity in testing the predictive utility of any individual
biomarker or clinical marker in high risk subjects for conversion to AD, unless each factor is not
associated with each other. For example, if subjects are recruited from different sites, then
regrouped by biomarker profile, those recruited from tertiary memory clinics are likely to both
progress to AD faster and have positive biomarker or clinical marker profiles, whatever biomarker
or clinical marker is used. Therefore in testing predictive utility for conversion to AD, comparing
between at least two or more biomarkers or clinical markers, may enhance study quality.
All dementia neuropathological studies are designed based on neuropathologies we currently
know how to identify. Neuropathologies that we do not know how to identify due to limita-
tions in current histopathological staining techniques are pathologies that are not studied.
Should they in fact be clinically relevant, we are unable to know this.
In order to test the concept that early intervention before disruption of neuronal integrity is
key in successful therapy, subjects will have to be recruited at a stage where there is minimal
disruption of neuronal integrity. However, if these subjects are recruited at too early stages of
disease, they may not decline for the same reason that they are recruited, so results may be
negative and they are not considered to have a disease but a syndrome. Having to recruit
subjects with a syndrome but not a disease classification makes it harder to apply for research
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funding. If subjects are recruited after downstream processes have began, even though there is
minimal disruption of neuronal integrity at enrolment, the treatment may not work. Yet it is
easier to raise money when subjects are considered to have a disease.
3.6. Discordant biomarker results
Phenotypes can range between being atypical to being unambiguous. Clinical labels lose
credibility when challenged by biomarker evidence which are themselves not perfect. It is
possible for an amyloid PET scan to be positive and the CSF Aβ level to be high, and vice
versa. It is possible for tracer uptake to be concentrated only on one brain region unilaterally. It
is possible for tracer uptake to increase rapidly between serial scans within a relatively short
space of time. It is possible for tracer uptake to decrease between serial scans. False negatives,
albeit rare, have been reported with Pittsburgh compound B (PiB) scans [34]. Even pathologi-
cal confirmation, which is the gold standard, is not an exact science. Conflicting biomarkers
add complexity to diagnosis and prognostication. It is important to apply Bayesian logic (i.e.
post-test probability is affected by pre-test probability and the robustness of the test) when
considering differentials.
3.7. Clinical diagnosis versus clinical deterioration
Clinical diagnosis does not necessarily predict deterioration over time. It is appropriate to
conclude that having a positive amyloid scan will result in AD patterns of deficits developing,
but this does not exclude significant co-morbid conditions from becoming the predominant
contributing factor in cognitive or functional decline. Older persons may be living long enough
to accumulate another threat to the body. Thus neurodegenerative pathologies may be more
relevant in pre-terminal decline than terminal decline. Death is a competing risk for seeing the
clinical syndrome develop, even though the pathology is there.
4. Principles and challenges in cognitive testing
4.1. Introduction
Cognitive tests demonstrate cognitive performance. They should be considered an adjunct tool
in the assessment and management of an underlying neurodegenerative condition. All tests
are based on paradigms on how we learn information. In order to detect deficits, tests are
designed to push people until they make errors. A low score does not diagnose dementia. A
high score does not exclude dementia. A single score cannot be considered in isolation.
Confidence that cognitive tests accurately reflect subject cognition is important. Tests require a
wide response distribution and evenness of scale to enable sensitive detection of clinical
changes and assessment of the degree of deficits. Sensitivity to cognitive disease and change
over time, enables tracking of disease progression, evaluation of treatment effectiveness, and
maintains focus on the symptoms and disease of interest. Measures should be able to capture
deficits, have low noise, and relate to biological markers. Characterising early presenters based
on neuropsychological test performance should be detailed enough to make sense, but not
overly precise—otherwise it can paradoxically complicate assessment and follow-up.
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Data is currently lacking in how well tests track with amyloid. Longitudinal examination of
different trajectories of cognitive decline over time can validate specific biomarker profiles,
help to elucidate underlying mechanisms of disease, and predict clinical outcome. The chal-
lenge in observational studies is to be selective yet inclusive of tests that can be operationalised
in all participants, and sensitive enough to track changes [7]. Regulatory agencies require that
measures are well experienced and understood [35]. Application of technology can enable
easier tailoring of cognitive and functioning assessment protocols to meet the needs of unique
populations or settings, and extend the possibility of administering assessments and delivering
interventions remotely [36].
Cognitive tests cannot extract specific unimodal factors alone. They all extract broad based
processes. No neuropsychological test is orthogonal because testing is affected by many pro-
cesses, like allocation of attention resources, language and executive function. All tests should be
empirically derived from actual patients, then refined to improve sensitivity, reduce variability,
and simplify use. When developing a test, having some overlap between measures to ensure
concurrent validity is worthwhile, but there should not be toomuch correlation either. Some tests
are more highly predictive than others. For example the semantic interference test was highly
predictive of decline from MCI to dementia over an average 30 month period compared with
standard memory tests such as memory for passage and visual reproduction [37].
4.2. The importance of pattern recognition
Cognitive testing is not specific for a neuropathology. External manifestations of results are
due to a combination of neuropathology and cognitive reserve. Patterns of deficits on different
sub-scores are important for the assessment of underlying pathology, so better testing
approaches should distinguish between memory and non-memory cognitive domains. The
possibility of a neurodegenerative disease is raised when there is a typical cerebral pattern of
spread [38–41]. This possibility is reduced when there is no overlap between deficit patterns on
sub-scores and neurodegenerative subtypes. For example, since living items is the most
impaired semantic category in AD, relatively poorer scores in this category compared with
others raises the odds of AD. The pattern of scores should be interpreted in context to the
patient’s situation, e.g. poor education, culturally and linguistically diverse background, co-
morbidities, conditions of the testing environment, hearing aids, glasses, tester, etc.
4.3. Difficulties with cognitive testing
Cognitive measures may not be able to detect subtle changes or effects of underlying neuropa-
thology due to cognitive reserve, ceiling effect, or floor effect. Cognitive measures should be
sufficiently sensitive and specific to detect the effects being tested for, while being clinically
meaningful at the same time. Delayed logical memory or face-name tests are examples of tests
that can well detect amyloid deposition in the brain [42, 43].
Cognition is a heterogeneous construct, so while more sensitive and precise measures may
emerge, there will be limits to applying them across different cohorts. Reference norms differ
for different patient groups. For example, IQ-adjusted norms are used to predict progressive
cognitive decline in highly intelligent older individuals [44]. People who have individualised
strategies for learning (that is, those with high cognitive reserve) will do much better in
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general, so neuropsychological testing can be quite noisy. Non-memory tests are generally less
predictive of dementia in those with more education. Neuropsychological screening tools like
the mini-mental state examination are cultural and language biased even with the use of an
interpreter [45]. Efficacy can be limited by ceiling effects and variability in subject performance
over time. Cognitive testing may be more subjective than biomarker measurements as results
can be influenced by the behaviour of persons conducting or taking the test, fatigue of the
patient, and time of the day. Cognitive testing is susceptible to attention deficits, so delirium,
depression, and distress can result in scores in the dementia range.
4.4. Non-linear decline trajectory
Cognitive decline in ageing and dementia follow a non-linear trajectory [46]. However, during
short time intervals of only 2–3 years, changes may appear to be linear. Acceleration over time
(i.e. the non-linearity) is usually clearly seen with data points 7 years and beyond. Cognitive
scales may be sensitive to early changes but do not work well later, or sensitive to changes in
the later stage and do not work well earlier. While considerable work needs to be conducted to
establish which tasks are sensitive at particular stages of the preclinical period, the rule of
thumb is that the earlier the test, is the less precise it is. Still there is an increasing interest in
developing tools to detect the earliest manifestations of cognitive decline in order to prescribe
remediation strategies or measure effectiveness of treatment approaches. The more sensitive
the measure, the less numbers are needed in a trial.
4.5. Composite scoring
Composite testing smooths individual scores to better average the overall score. A simple
approach by deriving composite scores from combining different tests can enable more equal-
ity of different tests, reduce noise and facilitate a statistically more simple analysis of relation-
ships between cognitive domains like memory and imaging data. This would simplify studies
that make comparison between groups.
The best neuropsychological test batteries are not necessarily the longest or the most compre-
hensive. A certain degree of precision is required, but there may be no need to be overly
precise. People do dread having their neuropsychological deficits pointed out, and it can be
emotionally difficult for them to sit through a battery of tests. The size of a battery matters not
as much as the quality of the precision of the battery in detecting degrees of cognitive deficits.
One way to validate such neuropsychiatric composite scores is to see if similarity of results can
be obtained from different cohorts. Memory composite scores like the ADNI-Mem have been
found to be comparable with other memory measures in the prediction of cognitive change
over time, and could also differentiate changes over time. Such composite scores were associ-
ated with neuroimaging parameters [47].
4.6. Serial scoring and practice effects
Serial assessments enable better cognitive evaluation than cross-sectional assessment. For exam-
ple, the trajectory pattern of serial scores helps to differentiate between dementia and delirium.
While serial assessments are better than cross-sectional assessments, they become subjected to
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practice effects. Practice or re-test effects occur in non-demented adults [48]. They involve
episodic memory in learning test content, procedural non-declarative learning for familiarisation
with task procedures, and anxiety reduction by desensitisation. Practice effects are not necessar-
ily a nuisance as they themselves comprise a test. For example, one study showed that the loss of
short-term practice effects portends a worse prognosis after 1 year in patients with MCI [49].
When the Cogstate was repeated four times a day, having attenuated practice effect in non-
demented participants detects MCI [50, 51].
5. Principles and challenges in biomarker use
5.1. Introduction
A biomarker is any identifiable biological measurement that can be objectively measured; that
accurately represents underlying pathology associated with disease, like blood, CSF, or imag-
ing; and that changes with risk or expression of disease. Biomarkers in dementia measure
directly, the neuropathology that is primarily responsible, like the amount of β-amyloid (Aβ)
plaques in the Alzheimer’s disease brain (e.g. CSF Aβ42 and Aβ amyloid PET), and indirectly,
their downstream effects, like the amount of neuronal damage (e.g. CSF tau and volumetric
MRI) or synaptic dysfunction (e.g. FDG PET). Biomarkers should not be confused with genetic
risk factors, e.g. Apolipoprotein E ε4 polymorphism.
The diagnostic goals of biomarkers in dementia are to ensure significant neuropathology is
present or not present in people at risk of developing dementia, so as to increase confidence in
making a dementia subtype diagnosis like AD or non-AD in atypical cases, to reduce subject
numbers in clinical studies, and to reduce heterogeneity in a study cohort. The prognostic
goals of biomarkers are to assess risk and proximity of future decline by serving as surrogate
outcome measures to demonstrate effects on downstream targets of neurodysfunction and
neurodegeneration, to help define the disease stage, and reduce trial duration. The
theragnostic goals of biomarkers are to serve as end point measures to prove engagement of
disease modifying treatment with Aβ plaques, and to select drug of choice.
Due to the added value that biomarkers bring, they enable us to hypothesise in a much more
rigorous way how we conduct dementia studies. For example, the development of disease-
modifying anti-amyloid therapies is now assisted by in vivo cerebral Aβ imaging to reduce the
sample size by better selection of eligible volunteers for trials and to evaluate the efficacy of
treatment. Biomarkers can help in planning which drugs are safe for AD drug trials by seeing
if there had been some unexpected outcome in the brain. This would potentially improve
safety, minimise cost which will in turn enable more drugs to be trialled while avoiding unsafe
ones. Nonetheless, at this point in time, biomarkers are not used routinely in most clinical
settings in dementia management. On top of limited access or support from current clinical
guidelines, no neurodegenerative disease modifying drugs are currently licenced for routine
use. However, should disease-modifying therapy become available, the issue of expanding
infrastructure to meet the demands for biomarkers will be a subject of further debate. The
potential for the usefulness of biomarkers is fully dependant on whether or not a cure for AD
or non-AD dementias can be found.
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The fundamental consideration with any assessment approach in dementia, whether with
clinical bedside tests or with biomarkers is how precise a measure is in determining what it is
meant to be detecting. To be used as surrogates for clinical measures, biomarkers need to be
validated as reflecting clinical and/or pathological disease processes, taking into account the
phase of disease where they have a high degree of specificity and sensitivity [52, 53].
Standardising procedures will reduce measurement errors in clinical trials. They should apply
similarly to everyone no matter what race, language or culture they come from. Ideally, the
biomarkers and clinical markers must be strongly associated, yet independent of each other, in
order to be used as recruitment criteria and as outcome measures, yet avoiding circularity.
However validating the relationship between biomarker change and cognitive outcome is an
imperfect science. Considerable challenges remain in establishing the relationship between
biological and cognitive measures throughout the chronology of the preclinical phase of AD.
A measurable biomarker needs to be operable clinically, have significant clinical implications if
results are positive, and have clinical utility in terms of improving confidence in diagnosing,
prognosticating or guiding treatment options. Unlike cognitive assessments, biomarkers offer
more objective results and are considered complimentary to memory testing. They are highly
valued for their ability to detect underlying structures or neuropathology in vivo. However the
evaluation of biomarkers is an expensive endeavour, and cannot be carried out without
collaboration between pharmaceuticals and public institutions.
The reproducibility of biomarker results can be affected by many factors. For example, dis-
crepancy of biomarkers and cognitive tests can happen because of a plateau of biomarkers
prior to cognitive change. Individual biomarkers of amyloid PET, MRI, FDG PET, and CSF in
the ADNI cohort vary in their rate of change during disease progression, such that they fit
better in sigmoidal models than linear models [54]. An ideal biomarker should have a sensi-
tivity, specificity, as well as positive and negative predictive values above 80% for whatever is
it supposed to be testing for [55, 56]. Biomarkers are expensive. Risks, benefits and costs have
to be discussed with the patient.
5.2. Operationalisation challenges
The challenges in operationalising biomarkers for clinical practice are: standardization of
techniques; harmonising practices between settings; and developing infrastructure for com-
munity access to access them. In applying biomarkers in the clinical setting, we need to
consider the noise and variability factors, whether these are going to present a critical issue
when it comes to trying to apply this in cross-sectional or longitudinal evaluation. Different
biomarkers provide different levels of certainty, are sensitive and specific at different disease
stages and in different disease subtypes. Cross-sectional data of single time-point measures
have less predictability than multiple measurements for seeing progression and outcomes in
longitudinal data, which then in turn limits on-going participation. For most biomarkers,
biomarker progressions are more associated with cognitive decline than baseline values [57].
This suggests that clinical trials which require recruiting at-risk subjects could be improved by
using progression rather than baseline values in biomarkers to enrich the study subjects.
Further studies are warranted to estimate the incremental effectiveness of improving clinical
trial statistical power by using biomarker progression criteria.
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Biomarkers should only offer additional information which we are unable to obtain during
routine history-taking, physical examination, and investigations. Their use is more appropriate
when there is some uncertainty in the clinical picture. All test results must be carefully
interpreted in the context of a patient’s clinical presentation. All tests have inherent limitations,
so over-reliance on any test without first considering relevant clinical information is likely to
lead to either over- or under-diagnosis, with potentially negative consequences. Hence we
need to exercise our clinical judgement to consider how additional information helps in
improving the probability of a dementia subtype diagnosis or in guiding treatment. Over-
emphasising biomarkers at the expense of appreciating the context of an individual case may
end up inappropriately prioritising less important aspects of a case.
Until an effect on a particular biomarker is reasonably likely to predict clinical benefit by
widespread evidence based agreement, it should not be used routinely as a surrogate outcome
measure in AD. The specific potential benefits of biomarkers as individuals transit from
normal to SCI, SCI to MCI, or MCI to dementia states need to be identified and measured.
Although further validation for currently available biomarkers is still required, advancement
in the biomarker field is currently approaching a plateau, as there is still no biomarker break-
through that can capture processes upstream to Aβ accumulation.
Finally, it is wrongly assumed that biomarkers are just as sensitive and specific for detecting
neuropathology across the age range and across the disease stage. For example, since the
standardised uptake value ratio (SUVR) is calculated using cerebellar grey matter as the
reference region, in late to advanced stages there will be amyloid build-up causing reduction
of SUVR. This has implications for longitudinal studies. The general reduction in amyloid load
after the plateau with ageing may falsely suggest that treatments are working.
5.3. Cerebral spinal fluid biomarkers
CSF tau levels increase because of tau leaking from neuronal injury, and CSFAβ levels decrease
possibly because Aβ is crystallising in the cortices. The potential benefits of using cerebral spinal
fluid biomarkers in AD research studies and prevention trials are the ability to: identify the
presence of AD pathologies in the absence of cognitive symptoms; evaluate therapeutic target
engagement; stage disease pathology; track progression of disease pathology; evaluate potential
therapy-related disease modification; cost effectively assess multiple analytes in a single sample;
and allow for better trial design with fewer subjects, shorter duration, and assessment of effects
on the underlying disease pathologies.
CSF biomarkers are currently not routinely recommended for individual use in clinical practice.
The disadvantage of CSF is that it requires a lumbar puncture. Not everyone is willing to have
one, and also there is increased use of anticoagulation treatment in the elderly. Hence is it not
suitable for population studies. Other challenges in the use of CSF include the lack of protocol
and assay standardisation, sub-optimal assay reproducibility, difficulties in defining normal vs.
abnormal cut-off values, misperception regarding safety, tolerability and utility of CSF collection
and analysis, and the need for assay development and validity in the presence of a therapeutic
agent, especially with antibody-based therapies. Agreement between CSF Aβ and florbetapir in
ADNI subjects is reasonable but not great (κ = 0.72) cross-sectionally and longitudinally [58].
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An analysis of within-site and inter-site assay reliability across seven centres using aliquots of
CSF from normal control subjects and AD patients showed the coefficient of variation was
5.3% for Aβ, 6.7% for t-tau, and 10.8% for p-tau within centre, and it was 17.9, 13.1 and 14.6%
for Aβ, t-tau, and p-tau respectively between centres [59]. The reason for the inter-laboratory
precision is not well understood.
5.4. Cut-offs
Determining the threshold of a positive or negative biomarker result is arbitrary to some
extent, and can be problematic. Yet it may significantly influence categories and outcomes.
The essential difference between MCI and those considered to have normal cognition is
evidence of objective impairment on cognitive test scores, even though cut-off scores are
arbitrarily defined.
Different approaches to determining cut-offs yield different degrees of positives, and form a
band of intermediates close to where the cut-offs are. A case can be made for cut-offs to be
modified by age rather than by merely depending on a simple number, but this will increase
complexity in the analyses. Examples of cut-off approaches include clustering analysis, 95th
percentile, iterative outlier approach, absolute cut-off (e.g. SUVR over 1.50 for PiB scans), and
greater than control mean plus two standard deviations.
CSF may be abnormal before PET and the discordance of low CSF Aβ42 levels with PiB
depends on the cut-offs for both [60]. Cases with discordance of both biomarkers are usually
cases where one or both biomarker results are around the cut-off.
Cut-offs can have implications in the design of AD trials. Lower cut-offs for amyloid positivity
ensure the sample subjects are more likely to have AD, and high cut-offs might avoid exposing
individuals to the risks of treatment with little chance of benefit.
6. Ethical challenges in the disclosure of biomarker results
6.1. Introduction
By and large, the medical community tends to blur the distinction between that which is kept
strictly for research, and that applied in routine clinical practice. At present, the boundaries
between current research guidelines in dementia research and clinical practice are not distinct.
Research criteria have a strong potential to impact clinical practice, such that terminologies
used in research settings easily become adopted into routine clinical practice.
Biomarkers in dementia give risk information only, and results can be inconclusive. Until a
cure is developed, the distance between advancements in diagnosis and treatment continues to
grow. A positive result is not a diagnosis. Not all with positive biomarker results will develop
AD. Potential harms with study participation include confusion over inconclusive results,
being given wrong diagnoses, stigmatisation, exploitation, discrimination, negative affective
reactions [61], escalation of insurance premiums [62], loss of the right to drive, additional work
conditions, and over-protection by law which can disadvantage employers.
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6.2. Disclosure of biomarker results
Disclosure of AD biomarker results is an important consideration in dementia trials. Study
designs that reveal increased risk may facilitate willingness to participate [63]. People par-
ticipate in studies because by knowing, they may potentially lower their risk, so they may
give their time and effort [64]. Similarly investigators are more in favour of disclosing scan
results to MCI than to healthy controls [65]. Communicating AD risk information has wide-
ranging ethical, psychological, behavioural, and social implications. People have different
views about whether or not they actually want to learn the results. Periodic assessments of
mood and well-being, providing access to appropriate care if there are problems, and pres-
ence of a designate partner for support are important considerations for participation in
studies.
The practice in ADNI has been not to disclose biomarker results to participants. Yet being in
the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study means that a partici-
pant is declaring that he has a positive amyloid PET scan. No disclosure would be needed in
the A4 study if it was designed as a three-arm randomised control trial with normal controls.
However this would require greater sample sizes escalating costs and complicating the
informed consent process.
Although biomarker use had been limited to research, clinicians in tertiary care are often
involved in biomarker research, and have an interest in the biomarker result to guide manage-
ment of their patients. Before biomarkers were officially approved for routine clinical use,
specialist clinicians were already applying biomarkers results informally in clinical practice
with the informed consent of their patients [65]. It was openness for accumulating such
experiences that drove thinking and enabled planning in biomarker validation studies. Clini-
cians are motivated to refer their patients for biomarker research studies, and patients are
motivated to participate, when they can benefit from obtaining a copy of the results even if
the biomarkers are not validated.
The more opportunities there are to use biomarkers in the clinical setting, the more we are
going to find cases of amyloid PET scans showing intermediate levels of amyloid in the brain,
particularly as cases requiring biomarkers to improve the diagnostic work-up tend to present
with some degree of diagnostic dilemma. While these cases are the hardest to diagnose, they
are also potential opportunities to further our understanding.
Both positive and negative biomarker results can benefit patients and families. A negative
result brings relief, and unnecessary further clinical testing is avoided. A positive result when
handled well enables early decision making when participants still have capacity, efficient
channelling of resources, and it also encourages healthy lifestyle change.
6.3. Evidence-based disclosure practice
The problem with AD is not merely whether one has plaques in the brain or not, or whether
people will want to know if they have the disease, but also how long do they have before they
have to move into residential care, and if they do have the disease whether they can be eligible
for costly drug treatment. One other consideration is what people will do once they get that
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information. While disease modifying treatment is currently only available by participating in
drug trials and may offer a glimmer of hope, it does have side effects and is not guaranteed to
work. Clinicians need to be sensitive to the negative impact breaking bad news can have on
patients, and be ready to provide support, like disease counselling. Regardless of whether
patients want to know, the disease will progress, and confidently diagnosing AD will help
them and their relatives make firm plans.
The need to mitigate the potential harm must be balanced by the patient’s right to know their
result. Cognitive biases in affective forecasting may over- or under-estimate reactions to nega-
tive events. Empirically validated methods of disclosing risk information can inform practice
and policy, and avoid speculation of how long and how intensely negative reactions will last
following disclosure. The full long term downstream effects of finding out and of how indi-
viduals and families interpret and handle the information is not known, so these people should
be followed to observe the effects of disclosure.
One study that followed 148 cognitively normal people participating in a randomised clinical
trial of genetic testing for Alzheimer’s disease for 1 year after risk assessment and E4 disclo-
sure showed that those tested as positive were 5.76 times more likely to have altered their long-
term care insurance than those who did not receive E4 genotype disclosure [62]. Nonetheless
the broader literature suggests that receiving a diagnosis of MCI or AD did not increase
depression or anxiety in patients nor their carers in the short term, and anxiety often decreased
[66]. One study that assessed the impact of genetic risk assessment on adult children of
people with AD showed a slight increase in the impact of event between E4 carriers and
non-carriers at 6 weeks, but the effect washed out at 6 months [67]. Hence E4 status can be
revealed safely to patients without risk of long-term depression or anxiety.
7. Final word
Other than finding a cure, promoting healthy brain ageing is also important. This can be done
by determining and promoting those factors that promote longevity and healthy brain ageing.
Promotion involves staying mentally and physically active, staying socially engaged, and
controlling cardiovascular risk factors like weight, blood pressure, cholesterol, and blood
sugar, quitting smoking and having a balanced diet.
The need to be persistent, to innovate and to move forward is urgent despite numerous
challenges. Whether we choose to address the conundrums or ignore them because of technical
difficulties, the tsunami of the dementia epidemic will hit us in a few short years. Fortunately
the dementia field has been very motivated. In spite of the numerous challenges in developing
new models of understanding, diagnostic criteria, clinical markers, biomarkers, treatment, and
improving diagnostic accuracy, the field is marching towards addressing, and intervening in,
AD in its early stages.
Finally, attention to the nuances and caveats, and applying little tweaks in study designs can
improve efficiency and study quality, reduce risk, and shed new insights.
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